11:09 EDT Regeneron (REGN) down 3% after appeals court decision in Amgen (AMGN) patent fight
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron, Sanofi presents results from ADEPT Phase 2/3 trial on Dupixent
- Regeneron’s treatment of lipodystrophy granted FDA orphan designation
- Regeneron announces EMA CHMP adopted positive opinion on linvoseltamab
- 3 Best Value Stocks to Buy Now, 2/27/2025, According to Analysts
- REGN Lawsuit Alert! Class Action Against Regeneron Pharmaceuticals, Inc.
Questions or Comments about the article? Write to editor@tipranks.com